Home
    Disclaimer
    ← Back to AL-LAD
    AL-LAD molecular structure

    AL-LAD Stats & Data

    Psychedelic Research-chemical
    Aladdin N-allyl-nor-lsd 6-allyl-6-nor-lsd allad
    NPS DataHub
    MW349.48
    FormulaC22H27N3O
    CAS65527-61-9
    IUPAC(6~{a}~{R},9~{R})-~{N},~{N}-diethyl-7-prop-2-enyl-6,6~{a},8,9-tetrahydro-4~{H}-indolo[4,3-fg]quinoline-9-carboxamide
    SMILESC=CCN1CC(C=C2C1Cc1cnc3cccc2c13)C(=O)N(CC)CC
    InChIKeyJCQLEPDZFXGHHQ-QRIPLOBPSA-N
    2020/5.2 Δ9 10-Ergolene; 2021/5.2 Δ9 10-Ergolene; 2022/5.2 Δ9 10-Ergolene
    Chemical Class Lysergamide
    Psychoactive Class Psychedelic
    Half-Life Unknown in humans; presumed similar order to LSD (approx. 3–5 hours) based on structural/pharmacodynamic similarity.

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (full)
    5-HT1 receptor agonist
    5-HT2C receptor agonist
    Dopamine D1 receptor agonist
    Dopamine D2 receptor agonist

    History & Culture

    AL-LAD was first synthesized and described in the scientific literature in 1976. The compound received further attention in 1984 when researchers Andrew J. Hoffman and David Nichols investigated it as part of a broader series of LSD analogues, which also included ETH-LAD and PRO-LAD. This academic interest culminated in 1997 when Alexander Shulgin documented the substance in his landmark book TiHKAL (Tryptamines I Have Known And Loved), providing a dose range of 80-160 µg and a duration of 6-8 hours. Shulgin characterized AL-LAD as "one of the several very potent compounds in a large series of nor-LSD analogues." Despite this early academic documentation, AL-LAD saw little to no recreational use until 2013, when it emerged on the online research chemical market. The compound quickly gained traction as a grey-market alternative to LSD, commonly marketed alongside other novel lysergamides such as 1P-LSD, ALD-52, and ETH-LAD. By 2015, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported its presence in the European drug market for the first time, marking its transition from an obscure research compound to a recognized designer drug. The substance is sometimes referred to by the street name "Aladdin."

    Subjective Effect Notes

    cognitive: In comparison to other psychedelics such as Psilocin, LSA and Ayahuasca, AL-LAD is significantly more stimulating and fast paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects.

    Effect Profile

    Curated + 100 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    10104.5
    Headspace Depth×3
    10103.7
    Auditory Effects×1
    10103.2
    Body Load / Somatic Effects×1
    10105.0
    Catalog Erowid BlueLight
    Based on reports from:
    Effect Index Nostalgic Forest — nervewing TiHKAL TiHKAL #1: AL-LAD Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki AL-LAD The Drug Users Bible AL-LAD

    Community Effects

    TripSit
    Positive
    euphoria visual enhancement music enhancement body high energy warmth
    Negative
    tachycardia

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; presumed similar order to LSD (approx. 3–5 hours) based on structural/pharmacodynamic similarity.
    Addiction Potential
    Low; not considered habit-forming or addictive. Tolerance develops rapidly with repeated use, similar to LSD.

    Tolerance Decay

    Full tolerance 3d Half tolerance 7d Baseline ~14d

    Rapid tolerance accrues after a single experience, similar to LSD. Cross-tolerance across serotonergic lysergamides is partial; spacing experiences by 2+ weeks reduces tolerance-related dose escalation. Data are inferred from LSD literature plus user reports for AL-LAD.

    Cross-Tolerances

    LSD
    70% ●●○
    Other lysergamides (e.g., ALD-52, 1P-LSD)
    60% ●○○

    Experience Report Analysis

    Erowid BlueLight
    75 Reports
    2012–2022 Date Range
    66 With Age Data
    33 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 100 experience reports (75 Erowid + 25 Bluelight)

    100 Reports
    123 Effects Detected
    61 Positive
    35 Adverse
    27 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 61

    Color Enhancement 68.0% 85%
    Music Enhancement 58.0% 87%
    Euphoria 53.0% 89%
    Empathy 42.0% 90%
    Stimulation 41.0% 84%
    Visual Trails 36.0% 84%
    Joy 36.0% 88%
    Focus Enhancement 35.0% 82%
    Morphing 32.0% 84%
    Awe 32.0% 83%
    Introspection 31.0% 82%
    Tactile Enhancement 28.0% 70%
    Melting/flowing 28.0% 86%
    Entity Imagery 28.0% 81%
    Thought Acceleration 28.0% 76%
    Surface Breathing 28.0% 84%
    Body High 27.0% 86%
    Contentment 24.0% 82%
    Fractal Imagery 20.0% 87%
    Patterning 20.0% 82%

    Adverse Effects 35

    Anxiety 54.0% 83%
    Confusion 32.0% 80%
    Muscle Tension 28.0% 85%
    Nausea 25.0% 71%
    Sadness 24.0% 78%
    Memory Suppression 22.7% 70%
    Thought Loops 17.0% 75%
    Fear 16.0% 86%
    Sweating 14.7% 70%
    Headache 14.0% 82%
    Depersonalization 12.0% 78%
    Thought Disorganization 12.0% 78%
    Increased Heart Rate 9.3% 70%
    Pupil Dilation 9.0% 78%
    Jaw Clenching 8.0% 85%
    Motor Impairment 8.0% 80%
    Crying 8.0% 85%
    Insomnia 8.0% 78%
    Psychosis 5.3% 70%
    Ataxia 4.0% 80%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Common (n=19) Strong (n=20)
    Visual Distortions 100.0% 95.0%
    Color Enhancement 73.7% 80.0%
    Anxiety 73.7% 75.0%
    Music Enhancement 68.4% 75.0%
    Confusion 36.8% 65.0%
    Empathy 42.1% 55.0%
    Focus Enhancement 36.8% 55.0%
    Muscle Tension 52.6% 30.0%
    Euphoria 52.6% 50.0%
    Stimulation 52.6% 40.0%
    Closed-Eye Visuals 52.6% 35.0%
    Open-Eye Visuals 31.6% 45.0%
    Sedation 42.1% 15.0%
    Memory Suppression 21.1% 40.0%
    Nausea 36.8% 10.0%

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 75 experience reports.

    Limited tier coverage — most reports fall within the Common / Strong range. Effects at other dose levels may not be represented.

    Oral dose range: 150.0–300.0 µg (median 150.0 µg)
    Effect Common (n=19) Strong (n=20)
    visual distortions
    100%
    95%
    		→
    color enhancement
    74%
    80%
    		→
    anxiety
    74%
    75%
    		→
    music enhancement
    68%
    75%
    		→
    confusion
    37%
    65%
    		↑
    empathy
    42%
    55%
    		↑
    focus enhancement
    37%
    55%
    		↑
    muscle tension
    53%
    30%
    		↓
    euphoria
    53%
    50%
    		→
    stimulation
    53%
    40%
    		↓
    closed-eye visuals
    53%
    35%
    		↓
    open-eye visuals
    32%
    45%
    		↑
    sedation
    42%
    15%
    		↓
    memory suppression
    21%
    40%
    		↑
    nausea
    37%
    10%
    		↓
    tactile enhancement
    10%
    35%
    		↑
    auditory effects
    21%
    30%
    		↑
    ego dissolution
    10%
    30%
    		↑
    introspection
    26%
    20%
    		↓
    body high
    21%
    25%
    		↑

    Showing top 20 of 31 effects

    Risk Escalation

    Sentiment Analysis

    Average frequency of positive vs adverse effects across dose tiers

    Common n=19
    9 positive 42.7% 11 adverse 27.3%
    Strong n=20
    10 positive 45.5% 9 adverse 31.7%
    View effect breakdown

    Adverse Effects

    Effect Common (n=19) Strong (n=20) Change
    Anxiety
    74%
    75%
    		1%
    Confusion
    37%
    65%
    		+76%
    Muscle Tension
    53%
    30%
    		-42%
    Memory Suppression
    21%
    40%
    		+89%
    Nausea
    37%
    10%
    		-72%
    Thought Loops
    16%
    25%
    		+58%
    Headache
    21%
    15%
    		-28%
    Sweating
    10%
    15%
    		+42%
    Pupil Dilation
    10%
    		— 0%
    Jaw Clenching
    10%
    		— 0%
    Increased Heart Rate
    10%
    		— 0%
    Motor Impairment —
    10%
    		0%

    Positive Effects

    Effect Common (n=19) Strong (n=20) Change
    Color Enhancement
    74%
    80%
    		8%
    Music Enhancement
    68%
    75%
    		9%
    Empathy
    42%
    55%
    		+30%
    Focus Enhancement
    37%
    55%
    		+49%
    Euphoria
    53%
    50%
    		-4%
    Stimulation
    53%
    40%
    		-23%
    Tactile Enhancement
    10%
    35%
    		+233%
    Introspection
    26%
    20%
    		-23%
    Body High
    21%
    25%
    		+18%
    Creativity Enhancement —
    20%
    		0%

    Dosage Distribution

    Dose distribution from experience reports

    Oral

    Median: 150.0 µg IQR: 150.0–300.0 µg n=24

    Sublingual

    Median: 300.0 µg IQR: 112.5–600.0 µg n=12

    Real-World Dose Distribution

    62K Doses

    From 73 individual dose entries

    Oral (n=36)

    Median: 0.15mg 25th: 0.15mg 75th: 0.3mg 90th: 0.33mg
    mg/kg median: 0.002 mg/kg 75th: 0.005

    Sublingual (n=21)

    Median: 0.15mg 25th: 0.07mg 75th: 0.3mg 90th: 0.45mg
    mg/kg median: 0.002 mg/kg 75th: 0.005

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Oral

    Median: 0.003 mg/kg IQR: 0.002–0.005 mg/kg n=22

    Unknown

    Median: 0.004 mg/kg IQR: 0.002–0.004 mg/kg n=10

    Sublingual

    Median: 0.003 mg/kg IQR: 0.001–0.006 mg/kg n=11

    Redose Patterns

    Redosing behavior across 60 reports

    16.7% Redosed
    1.2 Avg Doses
    120m Median Interval
    Read full reports on Erowid →

    Legal Status

    Not scheduled under the United Nations Convention on Psychotropic Substances
    Country Status Notes
    Austria Unscheduled (potentially controlled as analogue) Not specifically scheduled, but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as a structural analogue of LSD.
    Denmark Illegal Specifically named on the list of controlled substances as of August 25, 2015.
    Finland Banned Listed in a government decree banning psychoactive substances from the consumer market.
    France Illegal Prohibited under national drug control legislation.
    Germany NpSG controlled Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import for market distribution, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalty.
    Japan Controlled substance Designated as a controlled substance effective February 28, 2020.
    Latvia Controlled (as analogue) Although not officially scheduled by name, controlled as an LSD structural analogue under an amendment enacted June 1, 2015.
    Sweden Schedule I (Narcotic) Added to the Narcotic Drugs Punishments Act under Schedule I (substances without accepted medical use) on January 26, 2016. Listed in Medical Products Agency regulation HSLF-FS 2015:35 under multiple names including 6-allyl-6-nor-LSD.
    Switzerland Illegal (Verzeichnis E) Specifically named as a controlled substance under Verzeichnis E, effective December 1, 2015, as part of a broader scheduling of 21 novel psychoactive substances.
    Turkey Illegal Prohibited under national drug control legislation as of February 2016.
    United Kingdom Class A Specifically named in the Misuse of Drugs Act 1971 as a Class A controlled substance. The UK Advisory Council on the Misuse of Drugs recommended scheduling on June 10, 2014, notably without identifying any harm associated with its use. The ban was enacted January 6, 2015 via The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
    United States Unscheduled (Analogue Act applies) Not specifically scheduled at the federal level. However, as a structural analogue of the Schedule I substance LSD, it may be prosecuted under the Federal Analogue Act when sold, possessed, or consumed for human consumption. Research and analytical use are not subject to prosecution under this framework.

    Harm Reduction

    drugs.wiki

    AL-LAD is a lysergamide closely related to LSD, first synthesized in the 1970s and popularized as a research chemical in the 2010s. It is reported to produce a psychedelic experience similar to LSD but often described as more visually oriented, with a lighter, more euphoric, and less anxious character. It is usually sold on blotter paper and is active at microgram doses. There is little evidence of physical toxicity or long-term organ harm, but psychological risks (such as anxiety, panic, or precipitating mania/psychosis in vulnerable individuals) are possible, especially at high doses or in unsuitable settings. For drug checking, indole-positive reagents (Ehrlich) typically turn purple with lysergamides, and fresh LSD-family blotters fluoresce under UV; however, adulteration (e.g., adding tryptamine to mimic Ehrlich purple) can confound results—use multiple tests or a lab where possible. Avoid redosing for at least 3 hours; blotters vary in potency and occasionally contain unexpected substances with delayed onset. Store blotters cool, dark, and dry; UV light and heat accelerate degradation. Microgram potency makes precise measurement difficult—if handling liquid or powder, use volumetric dosing and label solutions clearly. AL-LAD is illegal in some jurisdictions.

    References

    Data Sources

    Cited References

    Drugs.wiki References

    ← Back to AL-LAD